Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 251 entries
Sorted by: Best Match Show Resources per page
Germline whole exome sequencing and large-scale replication identifies .

Oncotarget

Dicks E, Song H, Ramus SJ, Oudenhove EV, Tyrer JP, Intermaggio MP, Kar S, Harrington P, Bowtell DD, Group AS, Cicek MS, Cunningham JM, Fridley BL, Alsop J, Jimenez-Linan M, Piskorz A, Goranova T, Kent E, Siddiqui N, Paul J, Crawford R, Poblete S, Lele S, Sucheston-Campbell L, Moysich KB, Sieh W, McGuire V, Lester J, Odunsi K, Whittemore AS, Bogdanova N, Dürst M, Hillemanns P, Karlan BY, Gentry-Maharaj A, Menon U, Tischkowitz M, Levine D, Brenton JD, Dörk T, Goode EL, Gayther SA, Pharoah DPP.
PMID: 28881617
Oncotarget. 2017 Mar 03;8(31):50930-50940. doi: 10.18632/oncotarget.15871. eCollection 2017 Aug 01.

We analyzed whole exome sequencing data in germline DNA from 412 high grade serous ovarian cancer (HGSOC) cases from The Cancer Genome Atlas Project and identified 5,517 genes harboring a predicted deleterious germline coding mutation in at least one...

Cite
Dicks E, Song H, Ramus SJ, et al. Germline whole exome sequencing and large-scale replication identifies . Oncotarget. 2017;8(31):50930-50940doi: 10.18632/oncotarget.15871.
Dicks, E., Song, H., Ramus, S. J., Oudenhove, E. V., Tyrer, J. P., Intermaggio, M. P., Kar, S., Harrington, P., Bowtell, D. D., Group, A. S., Cicek, M. S., Cunningham, J. M., Fridley, B. L., Alsop, J., Jimenez-Linan, M., Piskorz, A., Goranova, T., Kent, E., Siddiqui, N., Paul, J., Crawford, R., Poblete, S., Lele, S., Sucheston-Campbell, L., Moysich, K. B., Sieh, W., McGuire, V., Lester, J., Odunsi, K., Whittemore, A. S., Bogdanova, N., Dürst, M., Hillemanns, P., Karlan, B. Y., Gentry-Maharaj, A., Menon, U., Tischkowitz, M., Levine, D., Brenton, J. D., Dörk, T., Goode, E. L., Gayther, S. A., & Pharoah, D. P. P. (2017). Germline whole exome sequencing and large-scale replication identifies . Oncotarget, 8(31), 50930-50940. https://doi.org/10.18632/oncotarget.15871
Dicks, Ed, et al. "Germline whole exome sequencing and large-scale replication identifies ." Oncotarget vol. 8,31 (2017): 50930-50940. doi: https://doi.org/10.18632/oncotarget.15871
Dicks E, Song H, Ramus SJ, Oudenhove EV, Tyrer JP, Intermaggio MP, Kar S, Harrington P, Bowtell DD, Group AS, Cicek MS, Cunningham JM, Fridley BL, Alsop J, Jimenez-Linan M, Piskorz A, Goranova T, Kent E, Siddiqui N, Paul J, Crawford R, Poblete S, Lele S, Sucheston-Campbell L, Moysich KB, Sieh W, McGuire V, Lester J, Odunsi K, Whittemore AS, Bogdanova N, Dürst M, Hillemanns P, Karlan BY, Gentry-Maharaj A, Menon U, Tischkowitz M, Levine D, Brenton JD, Dörk T, Goode EL, Gayther SA, Pharoah DPP. Germline whole exome sequencing and large-scale replication identifies . Oncotarget. 2017 Mar 03;8(31):50930-50940. doi: 10.18632/oncotarget.15871. eCollection 2017 Aug 01. PMID: 28881617; PMCID: PMC5584218.
Copy Download .nbib Format: NLM
Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors.

OncoTargets and therapy

Creelan BC, Gabrilovich DI, Gray JE, Williams CC, Tanvetyanon T, Haura EB, Weber JS, Gibney GT, Markowitz J, Proksch JW, Reisman SA, McKee MD, Chin MP, Meyer CJ, Antonia SJ.
PMID: 28919776
Onco Targets Ther. 2017 Aug 29;10:4239-4250. doi: 10.2147/OTT.S136992. eCollection 2017.

BACKGROUND: Omaveloxolone is a semisynthetic oleanane triterpenoid that potently activates Nrf2 with subsequent antioxidant function. We conducted a first-in-human Phase I clinical trial (NCT02029729) with the primary objectives to determine the appropriate dose for Phase II studies, characterize pharmacokinetic...

Cite
Creelan BC, Gabrilovich DI, Gray JE, et al. Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors. Onco Targets Ther. 2017;10:4239-4250doi: 10.2147/OTT.S136992.
Creelan, B. C., Gabrilovich, D. I., Gray, J. E., Williams, C. C., Tanvetyanon, T., Haura, E. B., Weber, J. S., Gibney, G. T., Markowitz, J., Proksch, J. W., Reisman, S. A., McKee, M. D., Chin, M. P., Meyer, C. J., & Antonia, S. J. (2017). Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors. OncoTargets and therapy, 104239-4250. https://doi.org/10.2147/OTT.S136992
Creelan, Ben C, et al. "Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors." OncoTargets and therapy vol. 10 (2017): 4239-4250. doi: https://doi.org/10.2147/OTT.S136992
Creelan BC, Gabrilovich DI, Gray JE, Williams CC, Tanvetyanon T, Haura EB, Weber JS, Gibney GT, Markowitz J, Proksch JW, Reisman SA, McKee MD, Chin MP, Meyer CJ, Antonia SJ. Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors. Onco Targets Ther. 2017 Aug 29;10:4239-4250. doi: 10.2147/OTT.S136992. eCollection 2017. PMID: 28919776; PMCID: PMC5587199.
Copy Download .nbib Format: NLM
Clinical validation of genetic variants associated with .

Oncotarget

Fasching PA, Häberle L, Rack B, Li L, Hein A, Ekici AB, Reis A, Lux MP, Cunningham JM, Ruebner M, Jenkins G, Fridley B, Schneeweiss A, Tesch H, Lichtenegger W, Fehm T, Heinrich G, Rezai M, Beckmann MW, Janni W, Weinshilboum RM, Wang L.
PMID: 29100455
Oncotarget. 2017 May 09;8(44):78133-78143. doi: 10.18632/oncotarget.17726. eCollection 2017 Sep 29.

Hematotoxicity is one of the major side effects of chemotherapy. The aim of this study was to examine the association between single nucleotide polymorphisms (SNPs) and hematotoxicity in breast cancer patients in a subset of patients of the SUCCESS...

Cite
Fasching PA, Häberle L, Rack B, et al. Clinical validation of genetic variants associated with . Oncotarget. 2017;8(44):78133-78143doi: 10.18632/oncotarget.17726.
Fasching, P. A., Häberle, L., Rack, B., Li, L., Hein, A., Ekici, A. B., Reis, A., Lux, M. P., Cunningham, J. M., Ruebner, M., Jenkins, G., Fridley, B., Schneeweiss, A., Tesch, H., Lichtenegger, W., Fehm, T., Heinrich, G., Rezai, M., Beckmann, M. W., Janni, W., Weinshilboum, R. M., & Wang, L. (2017). Clinical validation of genetic variants associated with . Oncotarget, 8(44), 78133-78143. https://doi.org/10.18632/oncotarget.17726
Fasching, Peter A, et al. "Clinical validation of genetic variants associated with ." Oncotarget vol. 8,44 (2017): 78133-78143. doi: https://doi.org/10.18632/oncotarget.17726
Fasching PA, Häberle L, Rack B, Li L, Hein A, Ekici AB, Reis A, Lux MP, Cunningham JM, Ruebner M, Jenkins G, Fridley B, Schneeweiss A, Tesch H, Lichtenegger W, Fehm T, Heinrich G, Rezai M, Beckmann MW, Janni W, Weinshilboum RM, Wang L. Clinical validation of genetic variants associated with . Oncotarget. 2017 May 09;8(44):78133-78143. doi: 10.18632/oncotarget.17726. eCollection 2017 Sep 29. PMID: 29100455; PMCID: PMC5652844.
Copy Download .nbib Format: NLM
Buffer Therapy for Cancer.

Journal of nutrition & food sciences

Ribeiro MD, Silva AS, Bailey KM, Kumar NB, Sellers TA, Gatenby RA, Ibrahim-Hashim A, Gillies RJ.
PMID: 24371544
J Nutr Food Sci. 2012 Aug 15;2:6.

Oral administration of pH buffers can reduce the development of spontaneous and experimental metastases in mice, and has been proposed in clinical trials. Effectiveness of buffer therapy is likely to be affected by diet, which could contribute or interfere...

Cite
Ribeiro MD, Silva AS, Bailey KM, et al. Buffer Therapy for Cancer. J Nutr Food Sci. 2012;2:6
Ribeiro, M. D., Silva, A. S., Bailey, K. M., Kumar, N. B., Sellers, T. A., Gatenby, R. A., Ibrahim-Hashim, A., & Gillies, R. J. (2012). Buffer Therapy for Cancer. Journal of nutrition & food sciences, 26.
Ribeiro, Maria de Lourdes C, et al. "Buffer Therapy for Cancer." Journal of nutrition & food sciences vol. 2 (2012): 6.
Ribeiro MD, Silva AS, Bailey KM, Kumar NB, Sellers TA, Gatenby RA, Ibrahim-Hashim A, Gillies RJ. Buffer Therapy for Cancer. J Nutr Food Sci. 2012 Aug 15;2:6. PMID: 24371544; PMCID: PMC3872072.
Copy Download .nbib Format: NLM
Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy.

Oncoimmunology

Chacon JA, Pilon-Thomas S, Sarnaik AA, Radvanyi LG.
PMID: 24319633
Oncoimmunology. 2013 Sep 01;2(9):e25581. doi: 10.4161/onci.25581. Epub 2013 Jul 03.

Co-stimulation through members of the tumor necrosis factor receptor (TNFR) family appears to be critical for the generation of T cells with optimal effector-memory properties for adoptive cell therapy. Our work suggests that continuous 4-1BB/CD137 co-stimulation is required for...

Cite
Chacon JA, Pilon-Thomas S, Sarnaik AA, et al. Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy. Oncoimmunology. 2013;2(9):e25581doi: 10.4161/onci.25581.
Chacon, J. A., Pilon-Thomas, S., Sarnaik, A. A., & Radvanyi, L. G. (2013). Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy. Oncoimmunology, 2(9), e25581. https://doi.org/10.4161/onci.25581
Chacon, Jessica Ann, et al. "Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy." Oncoimmunology vol. 2,9 (2013): e25581. doi: https://doi.org/10.4161/onci.25581
Chacon JA, Pilon-Thomas S, Sarnaik AA, Radvanyi LG. Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy. Oncoimmunology. 2013 Sep 01;2(9):e25581. doi: 10.4161/onci.25581. Epub 2013 Jul 03. PMID: 24319633; PMCID: PMC3850170.
Copy Download .nbib Format: NLM
Exploiting the co-reliance of tumours upon transport of amino acids and lactate: Gln and Tyr conjugates of MCT1 inhibitors.

MedChemComm

Nair RN, Mishra JK, Li F, Tortosa M, Yang C, Doherty JR, Cameron M, Cleveland JL, Roush WR, Bannister TD.
PMID: 27347360
Medchemcomm. 2016 May 01;7(5):900-905. doi: 10.1039/C5MD00579E. Epub 2016 Feb 23.

Glutamine and tyrosine-based amino acid conjugates of monocarboxylate transporter types 1 and 2 inhibitors (MCT1/2) were designed, synthesized and evaluated for their potency in blocking the proliferation of a human B lymphoma cell line that expresses the transporters Asct2,...

Cite
Nair RN, Mishra JK, Li F, et al. Exploiting the co-reliance of tumours upon transport of amino acids and lactate: Gln and Tyr conjugates of MCT1 inhibitors. Medchemcomm. 2016;7(5):900-905doi: 10.1039/C5MD00579E.
Nair, R. N., Mishra, J. K., Li, F., Tortosa, M., Yang, C., Doherty, J. R., Cameron, M., Cleveland, J. L., Roush, W. R., & Bannister, T. D. (2016). Exploiting the co-reliance of tumours upon transport of amino acids and lactate: Gln and Tyr conjugates of MCT1 inhibitors. MedChemComm, 7(5), 900-905. https://doi.org/10.1039/C5MD00579E
Nair, Reji N, et al. "Exploiting the co-reliance of tumours upon transport of amino acids and lactate: Gln and Tyr conjugates of MCT1 inhibitors." MedChemComm vol. 7,5 (2016): 900-905. doi: https://doi.org/10.1039/C5MD00579E
Nair RN, Mishra JK, Li F, Tortosa M, Yang C, Doherty JR, Cameron M, Cleveland JL, Roush WR, Bannister TD. Exploiting the co-reliance of tumours upon transport of amino acids and lactate: Gln and Tyr conjugates of MCT1 inhibitors. Medchemcomm. 2016 May 01;7(5):900-905. doi: 10.1039/C5MD00579E. Epub 2016 Feb 23. PMID: 27347360; PMCID: PMC4917231.
Copy Download .nbib Format: NLM
Enhancing oncology health care provider's sensitivity to cultural communication to reduce cancer disparities: a pilot study.

Journal of cancer education : the official journal of the American Association for Cancer Education

Quinn GP, Jimenez J, Meade CD, Muñoz-Antonia T, Gwede CK, Castro E, Vadaparampil ST, Simmons VN, McIntyre J, Crocker TT, Brandon TH.
PMID: 21479572
J Cancer Educ. 2011 Jun;26(2):322-5. doi: 10.1007/s13187-011-0223-1.

Under the auspices of a partnership grant to reduce cancer health disparities, Moffitt Cancer Center (MCC) partnered with the Ponce School of Medicine to identify the perceived cultural communication needs of MCC healthcare providers regarding Hispanic patients with limited...

Cite
Quinn GP, Jimenez J, Meade CD, et al. Enhancing oncology health care provider's sensitivity to cultural communication to reduce cancer disparities: a pilot study. J Cancer Educ. 2011;26(2):322-5doi: 10.1007/s13187-011-0223-1.
Quinn, G. P., Jimenez, J., Meade, C. D., Muñoz-Antonia, T., Gwede, C. K., Castro, E., Vadaparampil, S. T., Simmons, V. N., McIntyre, J., Crocker, T. T., & Brandon, T. H. (2011). Enhancing oncology health care provider's sensitivity to cultural communication to reduce cancer disparities: a pilot study. Journal of cancer education : the official journal of the American Association for Cancer Education, 26(2), 322-5. https://doi.org/10.1007/s13187-011-0223-1
Quinn, Gwendolyn P, et al. "Enhancing oncology health care provider's sensitivity to cultural communication to reduce cancer disparities: a pilot study." Journal of cancer education : the official journal of the American Association for Cancer Education vol. 26,2 (2011): 322-5. doi: https://doi.org/10.1007/s13187-011-0223-1
Quinn GP, Jimenez J, Meade CD, Muñoz-Antonia T, Gwede CK, Castro E, Vadaparampil ST, Simmons VN, McIntyre J, Crocker TT, Brandon TH. Enhancing oncology health care provider's sensitivity to cultural communication to reduce cancer disparities: a pilot study. J Cancer Educ. 2011 Jun;26(2):322-5. doi: 10.1007/s13187-011-0223-1. PMID: 21479572; PMCID: PMC3673723.
Copy Download .nbib Format: NLM
Localization of BRCA1 protein in breast cancer tissue and cell lines with mutations.

Cancer cell international

Tulchin N, Ornstein L, Dikman S, Strauchen J, Jaffer S, Nagi C, Bleiweiss I, Kornreich R, Edelmann L, Brown K, Bodian C, Nair VD, Chambon M, Woods NT, Monteiro AN.
PMID: 23855721
Cancer Cell Int. 2013 Jul 15;13(1):70. doi: 10.1186/1475-2867-13-70.

BACKGROUND: The breast and ovarian cancer susceptibility gene (BRCA1) encodes a tumor suppressor. The BRCA1 protein is found primarily in cell nuclei and plays an important role in the DNA damage response and transcriptional regulation. Deficiencies in DNA repair...

Cite
Tulchin N, Ornstein L, Dikman S, et al. Localization of BRCA1 protein in breast cancer tissue and cell lines with mutations. Cancer Cell Int. 2013;13(1):70doi: 10.1186/1475-2867-13-70.
Tulchin, N., Ornstein, L., Dikman, S., Strauchen, J., Jaffer, S., Nagi, C., Bleiweiss, I., Kornreich, R., Edelmann, L., Brown, K., Bodian, C., Nair, V. D., Chambon, M., Woods, N. T., & Monteiro, A. N. (2013). Localization of BRCA1 protein in breast cancer tissue and cell lines with mutations. Cancer cell international, 13(1), 70. https://doi.org/10.1186/1475-2867-13-70
Tulchin, Natalie, et al. "Localization of BRCA1 protein in breast cancer tissue and cell lines with mutations." Cancer cell international vol. 13,1 (2013): 70. doi: https://doi.org/10.1186/1475-2867-13-70
Tulchin N, Ornstein L, Dikman S, Strauchen J, Jaffer S, Nagi C, Bleiweiss I, Kornreich R, Edelmann L, Brown K, Bodian C, Nair VD, Chambon M, Woods NT, Monteiro AN. Localization of BRCA1 protein in breast cancer tissue and cell lines with mutations. Cancer Cell Int. 2013 Jul 15;13(1):70. doi: 10.1186/1475-2867-13-70. PMID: 23855721; PMCID: PMC3720266.
Copy Download .nbib Format: NLM
Comparing Two Exponential Distributions Using the Exact Likelihood Ratio Test.

Statistics in biopharmaceutical research

Han G, Schell MJ, Kim J.
PMID: 23814641
Stat Biopharm Res. 2012 Oct 01;4(4):348-356. doi: 10.1080/19466315.2012.698945.

The exact two-sided likelihood ratio test for testing the equality of two exponential means is proposed and proved to be the uniformly most powerful unbiased test. This exact test has advantages over two alternative approaches in that it is...

Cite
Han G, Schell MJ, Kim J. Comparing Two Exponential Distributions Using the Exact Likelihood Ratio Test. Stat Biopharm Res. 2012;4(4):348-356doi: 10.1080/19466315.2012.698945.
Han, G., Schell, M. J., & Kim, J. (2012). Comparing Two Exponential Distributions Using the Exact Likelihood Ratio Test. Statistics in biopharmaceutical research, 4(4), 348-356. https://doi.org/10.1080/19466315.2012.698945
Han, Gang, et al. "Comparing Two Exponential Distributions Using the Exact Likelihood Ratio Test." Statistics in biopharmaceutical research vol. 4,4 (2012): 348-356. doi: https://doi.org/10.1080/19466315.2012.698945
Han G, Schell MJ, Kim J. Comparing Two Exponential Distributions Using the Exact Likelihood Ratio Test. Stat Biopharm Res. 2012 Oct 01;4(4):348-356. doi: 10.1080/19466315.2012.698945. PMID: 23814641; PMCID: PMC3693095.
Copy Download .nbib Format: NLM
Do Breast Cancer Patients Tested in the Oncology Care Setting Share BRCA Mutation Results with Family Members and Health Care Providers?.

Journal of cancer epidemiology

Vadaparampil ST, Malo T, de la Cruz C, Christie J.
PMID: 22848222
J Cancer Epidemiol. 2012;2012:498062. doi: 10.1155/2012/498062. Epub 2012 Jul 15.

BRCA genetic test results provide important information to manage cancer risk for patients and their families. Little is known on the communication of genetic test results by mutation status with family members and physicians in the oncology care setting....

Cite
Vadaparampil ST, Malo T, de la Cruz C, et al. Do Breast Cancer Patients Tested in the Oncology Care Setting Share BRCA Mutation Results with Family Members and Health Care Providers?. J Cancer Epidemiol. 2012;2012:498062doi: 10.1155/2012/498062.
Vadaparampil, S. T., Malo, T., de la Cruz, C., & Christie, J. (2012). Do Breast Cancer Patients Tested in the Oncology Care Setting Share BRCA Mutation Results with Family Members and Health Care Providers?. Journal of cancer epidemiology, 2012498062. https://doi.org/10.1155/2012/498062
Vadaparampil, Susan T, et al. "Do Breast Cancer Patients Tested in the Oncology Care Setting Share BRCA Mutation Results with Family Members and Health Care Providers?." Journal of cancer epidemiology vol. 2012 (2012): 498062. doi: https://doi.org/10.1155/2012/498062
Vadaparampil ST, Malo T, de la Cruz C, Christie J. Do Breast Cancer Patients Tested in the Oncology Care Setting Share BRCA Mutation Results with Family Members and Health Care Providers?. J Cancer Epidemiol. 2012;2012:498062. doi: 10.1155/2012/498062. Epub 2012 Jul 15. PMID: 22848222; PMCID: PMC3403073.
Copy Download .nbib Format: NLM
Novel molecular markers of malignancy in histologically normal and benign breast.

Pathology research international

Nasir A, Chen DT, Gruidl M, Henderson-Jackson EB, Venkataramu C, McCarthy SM, McBride HL, Harris E, Khakpour N, Yeatman TJ.
PMID: 21785684
Patholog Res Int. 2011;2011:489064. doi: 10.4061/2011/489064. Epub 2011 Jul 10.

To detect the molecular changes of malignancy in histologically normal breast (HNB) tissues, we recently developed a novel 117-gene-malignancy-signature. Here we report validation of our leading malignancy-risk-genes, topoisomerase-2-alpha (TOP2A), minichromosome-maintenance-protein-2 (MCM2) and "budding-uninhibited-by-benzimidazoles-1-homolog-beta" (BUB1B) at the protein level. Using...

Cite
Nasir A, Chen DT, Gruidl M, et al. Novel molecular markers of malignancy in histologically normal and benign breast. Patholog Res Int. 2011;2011:489064doi: 10.4061/2011/489064.
Nasir, A., Chen, D. T., Gruidl, M., Henderson-Jackson, E. B., Venkataramu, C., McCarthy, S. M., McBride, H. L., Harris, E., Khakpour, N., & Yeatman, T. J. (2011). Novel molecular markers of malignancy in histologically normal and benign breast. Pathology research international, 2011489064. https://doi.org/10.4061/2011/489064
Nasir, Aejaz, et al. "Novel molecular markers of malignancy in histologically normal and benign breast." Pathology research international vol. 2011 (2011): 489064. doi: https://doi.org/10.4061/2011/489064
Nasir A, Chen DT, Gruidl M, Henderson-Jackson EB, Venkataramu C, McCarthy SM, McBride HL, Harris E, Khakpour N, Yeatman TJ. Novel molecular markers of malignancy in histologically normal and benign breast. Patholog Res Int. 2011;2011:489064. doi: 10.4061/2011/489064. Epub 2011 Jul 10. PMID: 21785684; PMCID: PMC3140260.
Copy Download .nbib Format: NLM
Reproducibility and Prognosis of Quantitative Features Extracted from CT Images.

Translational oncology

Balagurunathan Y, Gu Y, Wang H, Kumar V, Grove O, Hawkins S, Kim J, Goldgof DB, Hall LO, Gatenby RA, Gillies RJ.
PMID: 24772210
Transl Oncol. 2014 Feb 01;7(1):72-87. doi: 10.1593/tlo.13844. eCollection 2014 Feb.

We study the reproducibility of quantitative imaging features that are used to describe tumor shape, size, and texture from computed tomography (CT) scans of non-small cell lung cancer (NSCLC). CT images are dependent on various scanning factors. We focus...

Cite
Balagurunathan Y, Gu Y, Wang H, et al. Reproducibility and Prognosis of Quantitative Features Extracted from CT Images. Transl Oncol. 2014;7(1):72-87doi: 10.1593/tlo.13844.
Balagurunathan, Y., Gu, Y., Wang, H., Kumar, V., Grove, O., Hawkins, S., Kim, J., Goldgof, D. B., Hall, L. O., Gatenby, R. A., & Gillies, R. J. (2014). Reproducibility and Prognosis of Quantitative Features Extracted from CT Images. Translational oncology, 7(1), 72-87. https://doi.org/10.1593/tlo.13844
Balagurunathan, Yoganand, et al. "Reproducibility and Prognosis of Quantitative Features Extracted from CT Images." Translational oncology vol. 7,1 (2014): 72-87. doi: https://doi.org/10.1593/tlo.13844
Balagurunathan Y, Gu Y, Wang H, Kumar V, Grove O, Hawkins S, Kim J, Goldgof DB, Hall LO, Gatenby RA, Gillies RJ. Reproducibility and Prognosis of Quantitative Features Extracted from CT Images. Transl Oncol. 2014 Feb 01;7(1):72-87. doi: 10.1593/tlo.13844. eCollection 2014 Feb. PMID: 24772210; PMCID: PMC3998690.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 251 entries